Answers are grounded in this paper and cite their sources.
Randomized trial shows larotrectinib improves overall survival in TRK fusion differentiated thyroid carcinoma, suggesting effective therapy options.
Larotrectinib is the first-in-class, highly selective, central nervous system-active TRK inhibitor approved for tumour-agnostic use in TRK fusion cancer. It has previously demonstrated rapid and durable disease control and favourable safety in patients with advanced TRK fusion thyroid carcinoma (TC). After an additional 4 years of follow-up with inclusion of 2 additional patients, and utilising an independent review committee (IRC) to assess overall response rate (ORR), we report updated pooled analyses from 3 phase 1-2 larotrectinib clinical trials, focusing only on patients with TRK fusion differentiated TC (DTC). The primary endpoint was the IRC-determined ORR per RECIST v1.1. Duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety were also assessed. Twenty-four patients (papillary TC, n = 21; follicular TC, n = 2; poorly DTC, n = 1) were included (data cut-off: 20 July 2024). ORR was 79% (95% confidence interval [CI] 58-93); best responses were complete response in 3 (13%) patients, partial response in 16 (67%), stable disease in 3 (13%), progressive disease in 1 (4%) and not evaluable in 1 (4%). Median DoR and PFS were 35 (95% CI 22-not estimable [NE]) and 44 (35-NE) months, respectively; 6-year OS rate was 71% (95% CI 50-91). Six patients remained on treatment. Treatment-related adverse events (TRAEs) were mainly Grade 1/2; no patients permanently discontinued treatment due to TRAEs. Larotrectinib continues to demonstrate durable disease control, extended survival, and a favourable long-term safety profile in patients with advanced TRK fusion DTC requiring systemic therapy.
No takes yet. Share an insight, caveat, or question.
Waguespack et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: